Related Experiment Video
Updated: Jun 9, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice
Roberto Paz-Manrique1, Joseph A Pinto2, Henry L Gomez Moreno3
1CIONUR, Lima, Peru.
Abstract:
Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic bullet selectively eliminating cancer cells has evolved alongside bioengineering and cancer biology advancements. ADCs consist of a monoclonal antibody, linker, and cytotoxic payload, designed to target specific antigens on tumor cells while minimizing collateral damage. Mechanistically, ADCs are internalized via endocytosis, releasing the cytotoxic payload within the lysosome, potentially affecting neighboring tumor cells. ADC development has progressed through multiple generations, each addressing limitations of its predecessors. From gemtuzumab ozogamicin to trastuzumab emtansine (T-DM1), and now to third-generation agents such as trastuzumab deruxtecan (DS-8201) and disitamab vedotin (RC48), improvements have been made in target selectivity, potency, linker stability, and reduced off-target effects. Significant success has been seen in ADCs targeting human epidermal growth factor receptor 2 and trophoblast cell-surface antigen 2 antigens, especially in patients with breast cancer, including those resistant to previous therapies. The future of ADCs includes exploring new surface antigens, bispecific antibodies, immune-activating antibodies, radiopharmaceutical-loaded ADCs, and masked ADCs for tissue-specific activation. Ongoing research aims to optimize treatment efficacy while minimizing toxicity, expanding the potential of combination therapy. ADCs represent a promising frontier in precision cancer treatment, with continued research enhancing their potential in breast cancer and beyond. This review provides a comprehensive exploration of ADCs' evolution in breast cancer therapy, offering a molecular perspective to inform clinical practice and update colleagues on this dynamic field.
Insights
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy, offering targeted cell elimination. Ongoing research focuses on enhancing efficacy and minimizing toxicity for improved patient outcomes.
Area of Science:
- Oncology
- Biotechnology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) are engineered therapeutics combining targeted antibody delivery with potent cytotoxic agents.
- The concept, originating from Paul Ehrlich's "magic bullet" theory, has evolved significantly with advancements in bioengineering and cancer biology.
- ADCs comprise a monoclonal antibody, a linker, and a cytotoxic payload, designed for selective tumor cell targeting.
Purpose of the Study:
- To provide a comprehensive review of the evolution of antibody-drug conjugates (ADCs) in cancer therapy, particularly breast cancer.
- To offer a molecular perspective on ADC development, mechanism of action, and future directions.
- To update clinicians and researchers on the dynamic field of ADCs.
Main Methods:
- Review of historical development and generational advancements in ADC technology.
- Analysis of mechanistic pathways, including cellular internalization and payload release.
- Examination of clinical successes, particularly in breast cancer targeting HER2 and TROP2 antigens.
- Exploration of emerging ADC strategies and future research avenues.
Main Results:
- ADCs have progressed through multiple generations, with significant improvements in target selectivity, payload potency, linker stability, and reduced off-target effects.
- Notable successes include ADCs targeting HER2 and TROP2 antigens, demonstrating efficacy in breast cancer, even in treatment-resistant cases.
- Third-generation ADCs like trastuzumab deruxtecan and disitamab vedotin show enhanced therapeutic profiles.
- Future directions involve exploring novel antigens, bispecific antibodies, immune-activating payloads, and masked ADCs.
Conclusions:
- ADCs are a pivotal and evolving class of precision cancer therapeutics.
- Continued research is crucial for optimizing ADC efficacy, minimizing toxicity, and expanding their application in breast cancer and other malignancies.
- ADCs hold immense promise for improving cancer treatment outcomes through targeted cytotoxicity and potential combination therapies.
More Related Videos
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers